Brokerages Set Jazz Pharmaceuticals plc (NASDAQ:JAZZ) PT at $175.00

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has earned a consensus rating of “Moderate Buy” from the fifteen brokerages that are covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $175.00.

A number of equities analysts have commented on JAZZ shares. Piper Sandler reduced their target price on shares of Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating for the company in a report on Thursday, August 1st. Robert W. Baird decreased their target price on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating for the company in a research report on Thursday, August 1st. HC Wainwright restated a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, August 1st. Wells Fargo & Company reduced their price target on Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 1st. Finally, Needham & Company LLC reissued a “buy” rating and issued a $207.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, November 7th.

Jazz Pharmaceuticals Stock Down 2.1 %

NASDAQ:JAZZ opened at $121.65 on Thursday. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals has a 1-year low of $99.06 and a 1-year high of $134.17. The company has a 50-day moving average of $112.22 and a 200 day moving average of $110.35. The firm has a market cap of $7.35 billion, a PE ratio of 17.13, a price-to-earnings-growth ratio of 1.07 and a beta of 0.57.

Insider Activity at Jazz Pharmaceuticals

In related news, SVP Mary Elizabeth Henderson sold 1,410 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $108.30, for a total transaction of $152,703.00. Following the completion of the sale, the senior vice president now directly owns 14,531 shares in the company, valued at approximately $1,573,707.30. The trade was a 8.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Bruce C. Cozadd sold 1,000 shares of the firm’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $110.84, for a total transaction of $110,840.00. Following the completion of the transaction, the chief executive officer now directly owns 428,976 shares in the company, valued at approximately $47,547,699.84. This represents a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 6,110 shares of company stock worth $720,160 in the last 90 days. Corporate insiders own 4.20% of the company’s stock.

Institutional Trading of Jazz Pharmaceuticals

Several institutional investors have recently made changes to their positions in the company. MidWestOne Financial Group Inc. raised its holdings in Jazz Pharmaceuticals by 5.4% in the 3rd quarter. MidWestOne Financial Group Inc. now owns 22,063 shares of the specialty pharmaceutical company’s stock valued at $2,458,000 after buying an additional 1,134 shares during the period. Barclays PLC raised its position in Jazz Pharmaceuticals by 19.1% in the third quarter. Barclays PLC now owns 39,210 shares of the specialty pharmaceutical company’s stock valued at $4,369,000 after purchasing an additional 6,289 shares during the period. Public Employees Retirement System of Ohio acquired a new position in Jazz Pharmaceuticals during the third quarter worth $2,491,000. XTX Topco Ltd boosted its position in shares of Jazz Pharmaceuticals by 57.5% during the third quarter. XTX Topco Ltd now owns 11,631 shares of the specialty pharmaceutical company’s stock worth $1,296,000 after buying an additional 4,245 shares during the period. Finally, Krensavage Asset Management LLC grew its stake in shares of Jazz Pharmaceuticals by 1.1% in the third quarter. Krensavage Asset Management LLC now owns 110,257 shares of the specialty pharmaceutical company’s stock valued at $12,284,000 after buying an additional 1,181 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.